<document>

<filing_date>
2020-03-27
</filing_date>

<publication_date>
2020-10-08
</publication_date>

<priority_date>
2019-03-29
</priority_date>

<ipc_classes>
A61K39/00,A61P35/00,A61P37/04,C12N5/0783,C12N5/0784
</ipc_classes>

<assignee>
MYST THERAPEUTICS
</assignee>

<inventors>
LANGER, TIMOTHY J.
</inventors>

<docdb_family_id>
70334148
</docdb_family_id>

<title>
EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS
</title>

<abstract>
Provided herein are methods for ex vivo expansion of a T cells including tumor-reactive T cells, and compositions containing such T cells. Also provided are methods for treating diseases and conditions such as cancer using compositions of the present disclosure.
</abstract>

<claims>
WHAT IS CLAIMED:
1. A method for manufacturing tumor-reactive T cells, the method comprising:
(1) culturing T cells by a process that comprises:
(a) incubating a population of cells comprising T cells from a biological sample obtained from a subject that has a tumor with a first T cell stimulatory agent(s) under conditions to stimulate expansion of T cells of the population to produce a population of stimulated T cells;
(b) co-culturing the population of stimulated T cells in the presence of antigen presenting cells (APCs) under conditions in which the APCs have been induced to present one or more peptides from a tumor-associated antigen from the subject, thereby generating a population containing T cells comprising tumor reactive T cells;
(d) enriching from the co-culture the population of tumor reactive T cells reactive to the one or more peptides, wherein said tumor-reactive T cells comprise an endogenous TCR that is reactive to a tumor-associated antigen, thereby producing a population of T cells enriched for tumor-reactive T cells; and
(d) incubating the population of T cells enriched in tumor reactive T cells with a second T cell stimulatory agent(s) under conditions to stimulate expansion of T cells in the population; and
wherein one or more steps of the culturing is carried out in the presence of at least one T cell adjuvant that is an apoptosis inhibitor that inhibits caspase activation or activity; and
(2) harvesting cells produced by the method to produce a composition of expanded T cells enriched in tumor reactive T cells.
2. The method of claim 1, wherein the first or second T cell stimulatory agent(s) comprises the presence of one or more recombinant cytokines, wherein the incubating in the presence of the T cell stimulatory agent(s) is carried out prior to, during and/or subsequent to the incubating in the presence of the one or more T cell adjuvants.
3. The method of claim 1, wherein the incubation with the at least one T cell adjuvant is carried out during at least a portion of the coculturing.
4. The method of any of claims 1-3, wherein at least a portion of the incubating the population of T cells with the at least one T cell adjuvant is carried out concurrently with the incubating the population of T cells with the T cell stimulatory agent(s).
5. A method for manufacturing tumor reactive T cells, the method comprising:
(1) culturing T cells by a process comprising:
(a) incubating a population of cells comprising T cells from a biological sample from a subject that has a tumor with a first T cell stimulatory agent(s) comprising one or more recombinant cytokines under conditions to stimulate expansion of T cells in the population to produce a population of stimulated T cells, wherein the incubation with the one or more recombinant cytokines is in the presence of at least one T cell adjuvant that is an apoptosis inhibitor that inhibits caspase activation or activity;
(b) co-culturing the population of stimulated T cells in the presence of antigen presenting cells (APCs) under conditions in which the APCs have been induced to present one or more peptides from a tumor-associated antigen from the subject, thereby generating a population containing T cells comprising tumor reactive T cells;
(c) enriching tumor-reactive T cells from the co-culture, said tumor-reactive T cells comprising an endogenous TCR that is reactive to a tumor-associated antigen, thereby producing a population of T cells enriched for tumor-reactive T cells;
(d) incubating the population of T cells enriched for tumor-reactive T cells with a second T cell stimulatory agent(s) under conditions to stimulate expansion of cells of cells of the population of cells; and
(2) harvesting cells produced by the method.
6. The method of any of claims 1-5, wherein the at least one T cell adjuvant further comprises at least one costimulatory agonist.
7. The method of claim 6, wherein the incubating with the at least one costimulatory agonist and the apoptosis inhibitor is carried out simultaneously, intermittenttly or sequentially.
8. The method of any of claims 1-5, wherein the at least one T cell adjuvant further comprises at least one checkpoint inhibitor.
9. The method of claim 8, wherein the incubating with the at least one checkpoint inhibitor and the apoptosis inhibitor is carried out simultaneously, intermittenttly or sequentially.
10. A method for manufacturing tumor-reactive T cells, the method comprising:
(1) culturing T cells by a process that comprises:
(a) incubating a population of cells comprising T cells from a biological sample obtained from a subject that has a tumor with a first T cell stimulatory agent(s) under conditions to stimulate expansion of T cells of the population to produce a population of stimulated T cells;
(b) co-culturing the population of stimulated T cells in the presence of antigen presenting cells (APCs) under conditions in which the APCs have been induced to present one or more peptides from a tumor-associated antigen from the subject, thereby generating a population containing T cells comprising tumor reactive T cells;
(d) enriching from the co-culture the population of tumor reactive T cells reactive to the one or more peptides, wherein said tumor-reactive T cells comprise an endogenous TCR that is reactive to a tumor-associated antigen, thereby producing a population of T cells enriched for tumor-reactive T cells; and
(d) incubating the population of T cells enriched in tumor reactive T cells with a second T cell stimulatory agent(s) under conditions to stimulate expansion of T cells in the population; and
wherein one or more steps of the culturing is carried out in the presence of at least one T cell adjuvant that is a costimulatory agonist; and
(2) harvesting cells produced by the method to produce a composition of expanded T cells enriched in tumor reactive T cells.
11. The method of claim 10, wherein the first or second T cell stimulatory agent(s) comprises the presence of one or more recombinant cytokines, wherein the incubating in the presence of the T cell stimulatory agent(s) is carried out prior to, during and/or subsequent to the incubating in the presence of the one or more T cell adjuvants.
12. The method of claim 10, wherein the incubation with the at least one T cell adjuvant is carried out during at least a portion of the coculturing.
13. The method of any of claims 10-12, wherein at least a portion of the incubating the population of T cells with the at least one T cell adjuvant is carried out concurrently with the incubating the population of T cells with the T cell stimulatory agent(s).
14. A method for manufacturing tumor reactive T cells, the method comprising:
(1) culturing T cells by a process comprising:
(a) incubating a population of cells comprising T cells from a biological sample from a subject that has a tumor with a first T cell stimulatory agent(s) comprising one or more recombinant cytokinesunder conditions to stimulate expansion of T cells in the population to produce a population of stimulated T cells, wherein the incubation with the one or more recombinant cytokines is in the presence of at least one T cell adjuvant that is a costimulatory agonist;
(b) co-culturing the population of stimulated T cells in the presence of antigen presenting cells (APCs) under conditions in which the APCs have been induced to present one or more peptides from a tumor-associated antigen from the subject, thereby generating a population containing T cells comprising tumor reactive T cells;
(c) enriching tumor-reactive T cells from the co-culture, said tumor-reactive T cells comprising an endogenous TCR that is reactive to a tumor-associated antigen, thereby producing a population of T cells enriched for tumor-reactive T cells;
(d) incubating the population of T cells enriched for tumor-reactive T cells with a second T cell stimulatory agent(s) under conditions to stimulate expansion of cells of cells of the population of cells; and
(2) harvesting the expanded cells produced by the method.
15. The method of any of claims 10-14, wherein the at least one T cell adjuvant further comprises at least one apoptosis inhibitor.
16. The method of claim 15, wherein the incubating with the at least one apoptosis inhibitor and the checkpoint agonist is carried out simultaneously, intermittenttly or sequentially.
17. The method of any of claims 10-14, wherein the at least one T cell adjuvant further comprises at least one checkpoint inhibitor.
18. The method of claim 17, wherein the incubating with the at least one checkpoint inhibitor and the costimulatory agonist is carried out simultaneously, intermittenttly or sequentially.
19. A method for manufacturing tumor-reactive T cells, the method comprising:
(1) culturing T cells by a process that comprises:
(a) incubating a population of cells comprising T cells from a biological sample obtained from a subject that has a tumor with a first T cell stimulatory agent(s) under conditions to stimulate expansion of T cells of the population to produce a population of stimulated T cells;
(b) co-culturing the population of stimulated T cells in the presence of antigen presenting cells (APCs) under conditions in which the APCs have been induced to present one or more peptides from a tumor-associated antigen from the subject, thereby generating a population containing T cells comprising tumor reactive T cells;
(d) enriching from the co-culture the population of tumor reactive T cells reactive to the one or more peptides, wherein said tumor-reactive T cells comprise an endogenous TCR that is reactive to a tumor-associated antigen, thereby producing a population of T cells enriched for tumor-reactive T cells; and
(d) incubating the population of T cells enriched in tumor reactive T cells with a second T cell stimulatory agent(s) under conditions to stimulate expansion of T cells in the population; and
wherein one or more steps of the culturing is carried out in the presence of at least one T cell adjuvant that is a checkpoint inhibitor; and
(2) harvesting the expanded cells produced by the method.
20. The method of claim 19, wherein the first or second T cell stimulatory agent(s) comprises the presence of one or more recombinant cytokines, wherein the incubating in the presence of the T cell stimulatory agent(s) is carried out prior to, during and/or subsequent to the incubating in the presence of the one or more T cell adjuvants.
21. The method of claim 19, wherein the incubation with the at least one T cell adjuvant is carried out during at least a portion of the coculturing.
22. The method of any of claims 19-21, wherein at least a portion of the incubating the population of T cells with the at least one T cell adjuvant is carried out concurrently with the incubating the population of T cells with the T cell stimulatory agent(s).
23. A method for manufacturing tumor reactive T cells, the method comprising:
(1) culturing T cells by a process comprising:
(a) incubating a population of cells comprising T cells from a biological sample from a subject that has a tumor with a T cell stimulatory agent(s) comprising one or more recombinant cytokinesunder conditions to stimulate expansion of T cells in the population to produce a population of stimulated T cells, wherein the incubation with the one or more recombinant cytokines is in the presence of at least one T cell adjuvant that is a checkpoint inhibitor ;
(b) co-culturing the population of stimulated T cells in the presence of antigen presenting cells (APCs) under conditions in which the APCs have been induced to present one or more peptides from a tumor-associated antigen from the subject, thereby generating a population containing T cells comprising tumor reactive T cells;
(c) enriching tumor-reactive T cells from the co-culture, said tumor-reactive T cells comprising an endogenous TCR that is reactive to a tumor-associated antigen, thereby producing a population of T cells enriched for tumor-reactive T cells;
(d) incubating the population of T cells enriched for tumor-reactive T cells with a second T cell stimulatory agent(s) under conditions to stimulate expansion of cells of cells of the population of cells; and
(2) harvesting the expanded cells produced by the method.
24. The method of any of claims 19-23, wherein the at least one T cell adjuvant further comprises at least one apoptosis inhibitor
25. The method of claim 24, wherein the incubating with the at least one apoptosis inhibitor and the checkpoint inhibitor is carried out simultaneously, intermittenttly or sequentially.
26. The method of any of claims 19-23, wherein the at least one T cell adjuvant further comprises at least one costimulatory agonist.
27. The method of claim 26, wherein the incubating with the at least one costimulatory agonist and the checkpoint inhibitor is carried out simultaneously, intermittenttly or sequentially.
28. The method of any of claims 15, 16, 24 and 25, wherein the apoptosis inhibitor inhibits caspase activation or activity.
29. The method of any of claims 1-9, 15, 16, 24, 25 and 28, wherein the apoptosis inhibitor inhibits one or more of caspase 2, a caspase 8, a caspase 9, a caspase 10, a caspase 3, a caspase 6 or a caspase 7.
30. The method of any of claims 1-9, 15, 16, 24, 25, 28 and 29, wherein the apoptosis inhibitor is selected from the group consisting of Emricasan (IDN-6556, PF- 03491390), NAIP (neuronal apoptosis inhibitory protein; BIRCl), cIAPl and cIAP2 (cellular inhibitor of apoptosis 1 and 2; BIRC2 and BIRC3, respectively), XIAP (X-chromosome binding IAP; BIRC4), survivin (BIRC5), BRUCE (Apollon; BIRC6), livin (BIRC7) and Ts-IAP (testisspecific IAP; BIRC8), Wedelolactone, NS3694, NSCI and Zfluoromethyl ketone Z-VADFMK or a flouromethyl ketone variant thereof.
31. The method of any of clai s 1-9, 15, 1 6, 24, 25, and 28- 30, wherein the apoptosis inhibitor is a pan-caspase inhibitor that inhibits activation or activity of two or more caspases.
32. The method of any of claims 1-9, 15, 1 6, 24, 25, and 28- 31, wherein the apoptosis inhibitor is Z-VAD-FMK.
33. The method of any of claims 1-9, 15,1 6, 24, 25, and 28- 32, wherein the apoptosis inhibitor is selected from the group consisting of Z-FA-FMK, Z-VAD(OH)-FMK, ZDEVD-FMK, Z-VAD(OM2)-FMK, and Z-VDVAD-FMK.
34. The method of any of claims 1-9, 15, 1 6, 24, 25, and 28- 33, wherein the apoptosis inhibitor is added at a concentration of between at about 0.5 mM and at about 50 pM, between at about 0.5 pM and at about 40 pM, between at about 0.5 pM and at about 30 pM, between at about 0.5 pM and at about 20 pM, between at about 0.5 pM and at about 10 pM, between at about 0.5 pM and at about 5 pM, between at about 0.5 pM and at about 1 pM, between at about 1 pM, at about 1 pM at about 50 pM, between at about 1 pM and at about 40 pM, between at about 1 pM and at about 30 pM, between at about 1 pM and at about 20 pM, between at about 1 pM and at about 10 pM, between at about 1 pM and at about 5 pM, each inclusive, optionally wherein the concentration is at or about about 2 pM, at or about 10 pM or at or about 25 pM.
35. The method of any of claims 1-9, 15, 1 6, 24, 25, and 28- 33, wherein the apoptosis inhibitor is added at a concentration of between at about 0.5 pg/mL and at or about 25 pg/mL, between at or about 0.5 pg/mL and at or about 10 pg/mL, between at or about 0.5 pg/mL and at or about 5 pg/mL, between at or about 0.5 pg/mL and at or about 1 pg/mL, between at or about 1 pg/mL and at or about 25 pg/mL, between at or about 1 pg/mL and at or about 10 pg/mL, between at or about 1 pg/mL and at or about 5 pg/mL, between at or about 5 pg/mL and at or about 25 pg/mL, between at or about 5 pg/mL and at or about 10 pg/mL, or between at or about 10 pg/mL and at or about 25 pg/mL, each inclusive.
36. The method of any of claims 6, 7, 10-18, 26 and 27, wherein the costimulatory agonist is a tumor necrosis factor receptor superfamily (TNFRSF) agonist.
37. The method of any of claims 6, 7, 10-18, 26, 27 and 36, wherein the costimulatory agonist is an antibody or antigen-binding fragment that specifically binds a TNFRSF member or is a fusion protein comprising an extracellular domain or binding portion thereof of a ligand of a TNFRSF member.
38. The method of of claim 36, wherein the TNFRSF member is selected from 0X40, 4- IBB, GITR and CD27.
39. The method of any of claims 6, 7, 10-18, 26, 27 and 36-38, wherein the costimulatory agonist specifically binds 0X40.
40. The method of any of claims 6, 7, 10-18, 26, 27 and 36-39, wherein the costimulatory agonist is an antibody or antigen-binding fragment selected from Tavolixizumab, Pogalizumab, 11D4, 18D8, Hul 19-122, Hu 106-222, PF-04518600, GSK3174998, MEDI6469, BMS 986178 or 9B12, or is an antigen-binding fragment thereof .
41. The method of claim 40, wherein the costimulatory agonist is Tavolixizumab.
42. The method of any of claims 6, 7, 10-18, 26, 27 and 36-38, wherein the costimulatory agonist specifically binds 4- IBB.
43. The method of any of claims 6, 7, 10-18, 26, 27, 36-38 and 42 wherein the costimulatory agonist is urelumab or Utomilumab, or is an antigen-binding fragment of any of the foregoing.
44. The method of any of claims 6, 7, 10-18, 26, 27 and 36-38, wherein the costimulatory agonist specifically bind CD27.
45. The method of any of clai s 6, 7, 10-18, 26, 27, 36-38 and 44, wherein the costimulatory agonist is Varlilumab, or is an antigen-binding fragment of any of the foregoing.
46. The method of any of claims 6, 7, 10-18, 26, 27 and 36-38, wherein the costimulatory agonist specifically bind GITR.
47 The method of any of claims 6, 7, 10-18, 26, 27, 36-38 and 46, wherein the costimulatory agonist is MK-1248, or is an antigen-binding fragment of any of the foregoing.
48. The method of any of claims 6, 7, 10-18, 26, 27, 36-47, wherein the
costimulatory agonist is added at a concentration of between at about at or about at or about 0.5 pg/mL and at or about 25 pg/mL, between at or about 0.5 pg/mL and at or about 10 pg/mL, between at or about 0.5 pg/mL and at or about 5 pg/mL, between at or about 0.5 pg/mL and at or about 1 pg/mL, between at or about 1 pg/mL and at or about 25 pg/mL, between at or about 1 pg/mL and at or about 10 pg/mL, between at or about 1 pg/mL and at or about 5 pg/mL, between at or about 5 pg/mL and at or about 25 pg/mL, between at or about 5 pg/mL and at or about 10 pg/mL, and between at or about 10 pg/mL and at or about 25 pg/mL, each inclusive.
49. The method of any of claims 8, 9, 17, 18, 19-27, wherein the checkpoint inhibitor inhibits the activity of an immune checkpoint selected from the group consisting of PD-l/PDLl, CTLA-4, 0X40, LAG-3, TIM-3 and B7-H3.
50. The method of claim 49, wherein the immune checkpoint is selected from PD- 1/PD-Ll.
51. The method of claim 50, wherein the checkpoint inhibitor is an antiPD- 1 antibody, optionally wherein the antibody is selected from Pembrolizumab, cemiplimab, nivolumab, or is an antigen-binding fragment of any of the foregoing.
52. The method of claim 50 or claim 51 , wherein the checkpoint inhibitor is Pembrolizumab.
53. The method of claim 50, wherein the checkpoint inhibitor is an anti-PDLl antibody, optionally wherein the antibody is selected from avelumab, durvalumab and atezolizumab, or is an antigen-binding fragment of any of the foregoing.
54. The method of claim 49, wherein the immune checkpoint is 0X40.
55. The method of claim 54, wherein the checkpoint inhibitor is an anti-OX40L antibody, optionally wherein the antibody is Oxelumab or is an antigen-binding fragment thereof.
56. The method of claim 49, wherein the immune checkpoint is CTLA-4.
57. The method of claim 56, wherein the checkpoint inhibitor is an anti-CTLA-4 antibody, optionally wherein the antibody is Ipilimumab or is an antigen-binding fragment thereof.
58. The method of any of claims 8, 9, 17, 18, 19-27 and 49-57, wherein the checkpoint inhibitor is added at a concentration of between at about at or about at or about 0.5 pg/mL and at or about 25 pg/mL, between at or about 0.5 pg/mL and at or about 10 pg/mL, between at or about 0.5 pg/mL and at or about 5 pg/mL, between at or about 0.5 pg/mL and at or about 1 pg/mL, between at or about 1 pg/mL and at or about 25 pg/mL, between at or about 1 pg/mL and at or about 10 pg/mL, between at or about 1 pg/mL and at or about 5 pg/mL, between at or about 5 pg/mL and at or about 25 pg/mL, between at or about 5 pg/mL and at or about 10 pg/mL, and between at or about 10 pg/mL and at or about 25 pg/mL, each inclusive.
59. The method of any of claims 1-58, wherein the T cell adjuvant is added continuously during the one or more steps of the culturing, wherein the T cell adjuvant is replenished or replaced one or more times during the one or more steps of the culturing.
60. The method of any of claims 2-9, 11-19 and 20-59, wherein the T cell adjuvant is added continuously during the incubation with the one or more recombinant cytokines, wherein the T cell adjuvant is replenished or replaced one or more times during the incubation.
61. The method of any of claims 1-58, wherein the T cell adjuvant is added transiently during the one or more steps of the culturing, wherein the T cell adjuvant is added only one time during the one or more steps of culturing.
62. The method of any of claims 2-9, 11-19 and 20-58 and 61, wherein the T cell adjuvant is added transiently during the incubation with the one or more recombinant cytokines, wherein the T cell adjuvant is added only one time during the incubation.
63. The method of any of claims 1-62, wherein the first T cell stimulatory agent(s) comprise a recombinant cytokine selected from the group consisting of IL-10, IL-la, IL-5, IL-7, IL-12, IL-23p40, IL-16, IL-17A, IL-15, IL-22, IL-2, IL-4, IL-6, IL-8, IL-10, IL12p70, IL13, and IL-lb.
64. The method of any of claims 1-62, wherein the second T cell stimulatory agent(s) comprise a recombinant cytokine selected from the group consisting of IL-10, IL-la, IL-5, IL-7, IL-12, IL-23p40, IL-16, IL-17A, IL-15, IL-22, IL-2, IL-4, IL-6, IL-8, IL-10, IL12p70, IL13, and IL-lb.
65. The method of any of claims 2-9, 11-19 and 20-64, wherein the recombinant cytokine is selected from one or more of IL-2, IL-15, IL-7 and IL-21.
66. The method of any of claims 2-9, 11-19 and 20-65, wherein the one or more recombinant cytokine comprises recombinant IL-2.
67. A method for manufacturing tumor-reactive T cells, the method comprising:
(1) culturing T cells by a process that comprises:
(a) incubating a population of cells comprising T cells from a biological sample obtained from a subject that has a tumor with a first T cell stimulatory agent(s) comprising one or more recombinant cytokine selected from one or more of IL-7, IL-15 and IL-21 under conditions to stimulate expansion of T cells of the population to produce a population of stimulated T cells; (b) co-culturing the population of stimulated T cells in the presence of antigen presenting cells (APCs) under conditions in which the APCs have been induced to present one or more peptides from a tumor-associated antigen from the subject, thereby generating a population containing T cells comprising tumor reactive T cells;
(d) enriching from the co-culture the population of tumor reactive T cells reactive to the one or more peptides, wherein said tumor-reactive T cells comprise an endogenous TCR that is reactive to a tumor-associated antigen, thereby producing a population of T cells enriched for tumor-reactive T cells; and
(d) incubating the population of T cells enriched in tumor reactive T cells with a second T cell stimulatory agent(s) under conditions to stimulate expansion of T cells in the population; and
(2) harvesting the expanded cells produced by the method.
68. The method of claim 67, wherein the first T cell stimulatory agent(s) comprises one or more recombinant cytokines comprises IL-7 and IL-15.
69. The method of any of claims 66-68, wherein the first T cell stimulatory agent(s) further comprises recombinant IL-2.
70. The method of any of claims 66-69, wherein the first T cell stimulatory agent(s) does not comprise recombinant IL-2.
71. The method of any of claims 66-70, wherein the second T cell stimulatory agent(s) comprise one or more recombinant cytokine selected from the group consisting of IL- 10, IL-la, IL-5, IL-7, IL-12, IL-23p40, IL-16, IL-17A, IL-15, IL-22, IL-2, IL-4, IL-6, IL-8, IL- 10, IL12p70, IL13, and IL-lb.
72. The method of claim 71, wherein the recombinant cytokine is selected from one or more of IL-2, IL-15, IL-7 and IL-21.
73. The method of claim 71 or claim 72, wherein the one or more recombinant cytokine comprises recombinant IL-2.
74. The method of any of claims 2-9, 11-19 and 20-73, wherein the concentration of each of the one or more recombinant cytokine individually is 100 IU/mL to 6000 IU/mL.
75. The method of any of claims 2-9, 11-19 and 20-64, wherein the concentration of each of the one or more recombinant cytokine individually is from 300 IU/mL to 6000 IU/mL, 300 IU/mL to 3000 IU/mL, or 300 IU/mL to 1000 IU/mL, optionally wherein the concentration of each of the one or more recombinant cyokine is at or about 300 IU/mL or is at or about 1000 IU/mL.
76. The method of any of claims 1-75, wherein the second T cell stimulatory agent(s) further comprises an anti-CD3 antibody, optionally OKT3, optionally wherein the concentration of the anti-CD3 antibody is at or about 50 ng/mL.
77. The method of any of claims 1-76, wherein the antigen presenting cells are nucleated cells such as dendritic cells, mononuclear phagocytes, B lymphocytes, endothelial cells or thymic epithelium.
78. The method of any of claims 1-77, wherein the antigen presenting cells are dendritic cells.
79. The method of any of claims 1-78, wherein the antigen presenting cells are autologous to the subject or allogeneic to the subject.
80. The method of any of claims 1-79, wherein the antigen presenting cells.
81. The method of any of claims 1-80, wherein the T cells are autologous to the subject.
82. The method of any of claims 1-81, wherein the one or more peptides comprises at least one neoepitope from tumor-associated antigens from the subject.
83. The method of any of claims 1-82, wherein the co-culturing is carried out by a process comprising the steps of:
(a) identifying somatic mutations associated with one or more tumor-associated antigen by exome sequencing of healthy and tumor tissue from a subject;
(b) identifying at least one neoepitope of the one or more tumor-associated antigens;
(c) isolating a population of autologous T cells from a biological sample from the subject; and
(d) co-culturing the population of T cells with antigen presenting cells (APCs) that have been exposed to or contacted with the one or more peptides, said one or more peptides comprising the at least one neoepitope of the one or more tumor-associated antigens under conditions to present one or more of the peptides on the surface of a major histocompatibility complex (MHC), thereby generating the population of T cells comprising tumor-reactive T cells reactive to the one or more peptides.
84. The method of any of claims 1-83, wherein the MHC molecule is a class I molecule.
85. The method of any of claims 1-83, wherein the MHC molecule is a Class II molecule.
86. The method of any of claims 1-83, where in the MHC molecule is MHC class I and II.
87. The method of any of claims 1-86, wherein the T cells are CD4+ cells.
88. The method of any of claims 1-86, wherein the T cells are CD8+ cells.
89. The method of any of claims 1-86, wherein the T cells are CD4+ cells and CD8+ cells.
90. The method of any of claims 1-89, wherein the one or more peptide comprises an individual peptide or a pool of peptides.
91. The method of any of claims 1-90, wherein the one or more peptides are loaded on antigen presenting cells by transfection of in vitro transcribed synthesized minigene constructs encoding for the one or more peptides, optionally wherein the one or more peptides are flanked on each side by 12 amino acids from endogenous proteins, in tandem, wherein the transcribed minigene constructs generate individual peptides.
92. The method of any of claims 1-90, where the one or more peptides are loaded on antigen presenting cells by peptide pulse, optionally by electroporation.
93. The method of claim 92, wherein the one or more peptide is each individually 5- 30 amino acids, optionally 12-25 amino acids, optionally at or about 25 amino acids in length.
94. The method of claim 92 or claim 93, wherein:
the one or more peptides are a pool of peptides and the concentration of peptides in the pool of peptides for the peptide pulse is between at or about 0.001 pg/mL and at or about 40 pg/mL, 0.01 pg/mL and at or about 40 pg/mL, at or about 0.1 pg/mL and at or about 40 pg/mL, at or about 1 pg/mL and at or about 40 pg/mL, at or about 0.01 pg/mL and at or about 10 pg/mL or at or about 1 pg/mL and at or about 10 pg/mL; or
the one or more peptides is an individual peptide and the concentration of individual peptides for the peptide pulse is between at or about 0.00001 pg/mL and at or about 1 pg/mL, at or about 0.00001 pg/mL and at or about 0.1 pg/mL, at or about 0.00001 pg/mL and at or about 0.01 pg/mL, at or about 0.0001 pg/mL and at or about 1 pg/mL, at or about 0.0001 pg/mL and at or about 0.1 pg/mL, at or about 0.0001 pg/mL and at or about 0.1 pg/mL or at or about 0.0001 pg/mL and at or about 0.01 pg/mL.
95. The method of any of claims 92-94, wherein the concentration of individual peptides of the one or more peptide, on average, is from at or about 0.00001 pg/mL to at or about 0.01 pg/mL.
96. The method of any of claims 92-94, wherein the concentration of individual peptide of the one or more peptide, on average, is from at or about 0.0001 pg/mL and at or about 0.001 pg/mL.
97. The method of any of claims 1-96, wherein the co-culture ratio of antigen presenting cells to T Cells is between 20:1 and 1:1, between 15:1 and 1:1, between 10:1 and 1:1, between 5:1 and 1:1, between 2.5:1 and 1:1, between 1:20 and 1:1, between 1:15 and 1:1, between 1:10 and 1:1, between 1:5 and 1:1, or between 1:2.5 and 1:1.
98. The method of any of claims 1-97, wherein the co-culture ratio of antigen presenting cells to T cells is or is about 1:1.
99. The method of any of claims 1-98, wherein the co-culturing is for 2 hours to 24 hours.
100. The method of any of claims 1-99, wherein the co-culturing is for at or about 6 hours.
101. The method of any of claims 1-100, wherein the enriching for the tumor reactive T cells comprises selection of T cells surface positive for the one or more T cell activation markers.
102. The method of claim 101, wherein the one or more T cell activation marker is selected from the group consisting of CD107, CD107a, CD39, CD103, CD137 (4-1BB), CD59, CD69, CD90, CD38, CD30, CD154, CD252, CD134, CD258, CD256, PD-1, TIM-3 and LAG- 3.
103. The method of any of claims 1-102, wherein the one or more T cell activation marker is selected from the group consisting of CD38, CD39, CD6, CD90, CD 134 and CD 137.
104. The method of any of claims 1-103, wherein the one or more T cell activation marker is CD 134 and/or CD 137.
105. The method of any of claims 1-104, wherein the one or more T cell activation marker is selected from the group consisting of CD107, CD107a, CD39, CD103, CD59, CD90, CD38, CD30, CD154, CD252, CD134, CD258 and CD256.
106. The method of any of claims 1-102 and 105, wherein the one or more T cell activation marker is selected from the group consisting of CD107a, CD39, CD103, CD59, CD90 and CD38.
107. The method of any of claims 1-102, 105 and 106, wherein the one or more T cell activation marker comprises at least two markers selected from CD107a and CD39, CD107a and CD103, CD107a and CD59, CD107a and CD90, CD107a and CD38, CD39 and CD103, CD39 and CD59, CD39 and CD90, CD39 and CD38, CD103 and CD59, CD103 and CD90,
CD 103 and CD38, CD59 and CD90, CD59 and CD38 and CD90 and CD38.
108. The method of any of claims 105-107 wherein the one or more T cell activation marker further comprises CD 137.
109. The method of claim 108, wherein the one or more T cell activation marker comprises at least two markers selected from CD 107a and CD 137, CD38 and CD 137, CD 103 and CD137, CD59 and CD137, CD90 and CD137 and CD38 and CD137.
110. The method of any of claims 103-109, wherein the one or more T cell activation marker further comprises at least one marker selected from the group consisting of PD-1, TIM-3 and LAG-3.
111. The method of any of claims 101-110, wherein the selecting T cells surface positive for the one or more T cell activation markers is by flow cytometry, optionally carried out by automated high-throughput flow cytometry, optionally by the FX500 cell sorter or Miltenyi Tyto cell sorter.
112. The method of claim 111, wherein 1 run, 2 runs, 3 runs or 4 runs by flow cytometry is carried out to enrich the tumor-reactive T cells from the sample.
113. The method of any of claims 1-112, wherein one or more of the steps of the method is carried out in a closed system.
114. The method of any of claims 1-113, wherein the incubating with the first T cell stimulatory agent(s) is for 7 to 21 days, optionally 7 to 14 days.
115. The method of any of claims 1-114, wherein the incubating with the first T cell stimulatory agent(s) is in a closed system.
116. The method of any of claims 1-115, wherein the incubating with the first T cell stimulatory agent(s) is in a gas permeable culture vessel.
117. The method of any of claims 1-116, wherein the incubating with the first T cell stimulatory agent(s) is performed using a bioreactor.
118. The method of any of claims 1-117, wherein the incubating with the second T cell stimulatory agent(s) is for 7 to 21 days, optionally 7 to 14 days.
119. The method of any of claims 1-118, wherein the incubating with the second T cell stimulatory agent(s) is in a closed system.
120. The method of any of claims 1-119, wherein the incubating with the second T cell stimulatory agent(s) is in a gas permeable culture vessel.
121. The method of any of claims 1-119, wherein the incubating with the second T cell stimulatory agent(s) is performed using a bioreactor.
122. The method of any of claims 1-121, wherein harvesting is carried out within 30 days after initiation of the culturing and/or the enriching of T cells comprising tumor-reactive cells.
123. The method of any of claims 1-122, wherein the cells are harvested at a timepoint up to 30 days after the initation of the culturing, optionally 7 to 30 days, 7 to 20 days, 7 to 14 days, 7 to 10 days, 10 to 20 days, 10 to 14 days or 14 to 20 days after the initiation of the culturing.
124. The method of any of claims 1-123, wherein the subject exhibits a a cancer.
125. The method of any of claim 1-124, where a composition of comprising expanded cells produced by the method are used to treat the cancer in the subject.
126. The method of any of claims 1-125, wherein the tumor is a tumor of an epithelial cancer.
127. The method of any of claims 1-126, wherein the tumor is a tumor of a melanoma, lung squamous, lung adenocarcinoma, bladder cancer, lung small cell cancer, esophageal cancer, colorectal cancer (CRC), cervical cancer, head and neck cancer, stomach cancer or uterine cancer.
128. The method of any of claims 1-127, wherein the tumor is a tumor of a non-small cell lung cancer (NSCLC), CRC, ovarian cancer, breast cancer, esophageal cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma cancer, endometrial cancer, optionally wherein the breast cancer is HR+/Her2- breast cancer, triple negative breast cancer (TNBC) or HER2+ breast cancer.
129. The method of any of claims 1-128, wherein the biological sample is a peripheral blood sample, a lymph node sample, or a tumor sample.
130. The method of claim 129, wherein the biological sample is a peripheral blood sample and the peripheral blood sample is collected by a blood draw or by apheresis, optionally wherein the apheresis is leukapheresis.
131. The method of claim 129, wherein the biological sample is a lymph node sample or a tumor sample, wherein the sample is collected by a needle biopsy, optionally a core needle biopsy or a fine-needle aspiration.
132. The method in any of claim 1-131, wherein the population of cells comprising T cells comprise tumor infiltrating lymphocytes, lymph lymphocytes or peripheral blood mononuclear cells.
133. The method of any of claims 1-132, wherein the biological sample is a tumor and the population of cells comprising T cells comprise tumor infiltrating lymphocytes.
134. The method of any of claims 1-133, wherein the biological sample is a resected tumor and the population of cells comprising T cells are one or more tumor fragments from the resected tumor.
135. The method of claim 134, wherein the one or more tumor fragments are seeded for incubation with the first T cell stimulatory agent(s) at about 1 tumor fragment per 2 cm2 .
136. The method of any of claims 1-134, wherein the tumor is a melanoma.
137. The method of any of claims 1-134, wherein the biological sample is a resected tumor and the population of cells comprising T cells are processed as a single cell suspension by homogenization and/or enzymatic digestion of one or more tumor fragments from the resected tumor.
138. The method of any of claims 1-134, wherein the biological sample is a resected tumor and the population of cells comprising T cells are a single cell suspension processed by homogenization and enzymatic digestion of one or more tumor fragments from the resected tumor.
139. The method of claim 137 or claim 138, wherein the enzymatic digestion is by incubation with a collagenase, optionally collagenase IV or collagenase I/II.
140. The method of any claims 137-139, wherein the population of cells comprising T cells are seeded for incubation with the first T cell stimulatory agent(s) at about 5 x 10s to at or about 2 x 106 total cells per 2 cm2.
141. The method of any of claims 1-135 and 137-140, wherein the tumor is a colorectal cancer (CRC).
142. The method of any of claims 1-141, wherein the method results in a foldexpansion of T cells or in a fold-expansion of tumor reactive T cells that is at least at or about 2- fold, at least at or about 5-fold, at least at or about 10-fold, at least at or about 25-fold, at least at or about 50-fold, at least at or about 100-fold, at least at or about 250-fold, at least at or about 500-fold, at least at or about 1000-fold, or more.
143. The method of any of claims 1-142, wherein the composition of expanded cells are able to produce IFNgamma at a concentration of greater than at or about 30 pg/mL, optionally greater than at or about 60 pg/mL, following antigen-specific stimulation.
144. The method of any of claims 1-143, comprising formulating the harvested cells with a cryoprotectant.
145. A composition comprising expanded T cells enriched in tumor reactive T cells produced by the method of any of claims 1-144.
146. A composition of claim 145 comprising a pharmaceutically acceptable excipient..
147. The composition of claim 145 or claim 146, wherein the T cells are CD3+ T cells or comprise CD4+ T cells and/or CD8+ T cells.
148. The composition of any of claims 145-147, wherein the T cells comprise CD4+
T cells and CD8+ T cells, wherein the ratio of CD8+ T cells to CD4+ T cells is between at or about 1 :100 and at or about 100: 1, between at or about 1 :50 and at or about 50:1, between at or about 1 :25 and at or about 25:1, between at or about 1 : 10 and at or about 10: 1, between at or about 1 :5 and at or about 5:1, or between at or about 1:2.5 and at or about 2.5: 1.
149. The composition of any of claims 145-148, wherein the number of tumor reactive T cells or total T cells surface positive for the T cell activation marker, or of viable cells thereof, in the composition is between at or about 0.5 x 108 and at or about 50 x 109, between at or about 0.5 x 108 and at or about 30 x 109, between 0.5 x 108 and at or about 12 x 109, between at or about 0.5 x 108 and at or about 60 x 108, between at or about 0.5 x 108 and at or about 15 x 108, between at or about 0.5 x 108 and at or about 8 x 108, between at or about 0.5 x 108 and at or about 3.5x 108, between at or about 0.5 x 108 and at or about 1 x 108, between 1 x 108 and at or about 50 x 109, between at or about 1 x 108 and at or about 30 x 109, between 1 x 108 and at or about 12 x 109, between at or about 1 x 108 and at or about 60 x 108, between at or about 1 x 108 and at or about 15 x 108, between at or about 1 x 108 and at or about 8 x 108, between at or about 1 x 108 and at or about 3.5x 108, between at or about 3.5 x 108 and at or about 50 x 109, between at or about 3.5 x 108 and at or about 30 x 109, between at or about 3.5 x 108 and at or about 12 x 109, between at or about 3.5 x 108 and at or about 60 x 108, between at or about 3.5 x 108 and at or about 15 x 108, between at or about 3.5 x 108 and at or about 8 x 108, between at or about 8 x 108 and at or about 50 x 109, between at or about 8 x 108 and at or about 30 x 109, between at or about 8 x 108 and at or about 12 x 109, between at or about 8 x 108 and at or about 60 x 108, between at or about 8 x 108 and at or about 15 x 108, between at or about 15 x 108 and at or about 50 x 109, between at or about 15 x 108 and at or about 30 x 109, between at or about 15 x 108 and at or about 12 x 109, between at or about 15 x 108 and at or about 60 x 108, between at or about 60 x 108 and at or about 50 x 109, between at or about 60 x 108 and at or about 30 x 109, between at or about 60 x 108 and at or about 12 x 109, between at or about 12 x 109 and at or about 50 x 109, between at or about 12 x 109 and at or about 30 x 109, or between at or about 30 x 109 and at or about 60 x 109, each inclusive.
150. The composition of any of claims 145-149, comprising a cyroprotectant.
151. The composition of any of claims 145- 150 that is sterile.
152. A method of treating a subject having a cancer, the method comprising administering to a subject having a tumor a therapeutic dose of the composition of any of claims 145-151.
153. The method of claim 152, wherein the therapeutically effective dose is between 1 x 109 and 10 x 109 T cells.
154. The method of claim 152 or claim 153, wherein the cells of the administered composition are autologous to the subject.
155. The method of any of claims 152-154, wherein the cancer is an epithelial cancer.
156. The method of claim any of claims 152-154, wherein the cancer is melanoma, lung squamous, lung adenocarcinoma, bladder cancer, lung small cell cancer, esophageal cancer, colorectal cancer, cervical cancer, head and neck cancer, stomach cancer or uterine cancer.
157. The method of any of claims 152-154, wherein the cancer is non-small cell lung cancer (NSCLC), CRC, ovarian cancer, breast cancer, esophageal cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma cancer, endometrial cancer, optionally wherein the breast cancer is HR+/Her2- breast cancer, triple negative breast cancer (TNBC) or HER2+ breast cancer.
</claims>
</document>
